GP
ABBV icon

Greenline Partners’s AbbVie ABBV Stock Holding History

Greenline Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$425K Sell
1,955
-30
-2% -$6.66K 0.05% 129
2025
Q4 		$454K Buy
1,985
+30
+2% +$6.83K 0.05% 126
2025
Q3 		$453K Buy
+1,955
New +$398K 0.06% 121
2025
Q2 		– Sell
-1,955
Closed -$410K – 146
2025
Q1 		$410K Buy
1,955
+50
+3% +$9.72K 0.06% 116
2024
Q4 		$339K Hold
1,905
– – 0.05% 121
2024
Q3 		$376K Hold
1,905
– – 0.05% 122
2024
Q2 		$325K Sell
1,905
-50
-3% -$8.28K 0.05% 116
2024
Q1 		$356K Hold
1,955
– – 0.06% 106
2023
Q4 		$303K Buy
1,955
+50
+3% +$7.29K 0.05% 109
2023
Q3 		$284K Hold
1,905
– – 0.05% 104
2023
Q2 		$257K Hold
1,905
– – 0.05% 108
2023
Q1 		$304K Hold
1,905
– – 0.06% 114
2022
Q4 		$308K Buy
1,905
+162
+9% +$24.8K 0.06% 117
2022
Q3 		$234K Hold
1,743
– – 0.05% 110
2022
Q2 		$267K Hold
1,743
– – 0.06% 107
2022
Q1 		$283K Hold
1,743
– – 0.05% 106
2021
Q4 		$236K Buy
+1,743
New +$206K 0.04% 116
2020
Q2 		– Sell
-13,477
Closed -$1.03M – 109
2020
Q1 		$1.03M Sell
13,477
-12,546
-48% -$1.07M 0.33% 68
2019
Q4 		$2.3M Sell
26,023
-8,840
-25% -$734K 0.58% 51
2019
Q3 		$2.64M Buy
34,863
+3,115
+10% +$214K 0.76% 44
2019
Q2 		$2.31M Sell
31,748
-3,168
-9% -$249K 0.73% 42
2019
Q1 		$2.81M Sell
34,916
-6,089
-15% -$498K 0.92% 41
2018
Q4 		$3.87M Hold
41,005
– – 1.21% 32
2018
Q3 		$3.87M Buy
41,005
+1,245
+3% +$118K 1.21% 32
2018
Q2 		$3.68M Buy
39,760
+15,916
+67% +$1.55M 1.21% 31
2018
Q1 		$2.26M Buy
23,844
+15,244
+177% +$1.67M 0.75% 38
2017
Q4 		$832K Buy
+8,600
New +$811K 0.28% 54

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Greenline Partners's ABBV Position: Q1 2026 in Review

Greenline Partners reduced its AbbVie (ABBV) stake by 1.5% in Q1 2026, selling an estimated $6.66K and leaving 1,955 shares worth $425K. The position accounts for 0.05% of the portfolio, ranked #129.

Greenline Partners first reported a position in ABBV in Q4 2017 and has held it in 27 quarters since. The position peaked at $3.87M in Q4 2018. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Greenline Partners held 1,955 shares of AbbVie worth $425K as of Q1 2026.
  • Greenline Partners sold 30 AbbVie shares in Q1 2026, an estimated $6.66K.
  • AbbVie made up 0.05% of Greenline Partners's portfolio in Q1 2026, its #129 holding.
  • Greenline Partners first reported a position in AbbVie in Q4 2017 and has held it in 27 quarters since.
  • Greenline Partners's AbbVie position peaked at $3.87M in Q4 2018.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Greenline Partners's 13F filing for Q1 2026, filed 15 May 2026.